Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Perampanel Clear all
Terminated Not applicable Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT03020797
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Perampanel, Placebo Oral Tablet
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 2, 2026, 11:33 PM EDT
Not listed Phase 4 Interventional

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

NCT04118829
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Perampanel
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

NCT01396577
View directory record Official record
Conditions
Healthy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

NCT00154063
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
E2007, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

NCT00505284
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, E2007 (2 mg), E2007 (4 mg), E2007 (6 mg), E2007 (8 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

NCT03376997
View directory record Official record
Conditions
Healthy Participants
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

NCT04502589
View directory record Official record
Conditions
Alcohol Disorders
Interventions
Perampanel Tablet, Disulfiram
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 2, 2026, 11:33 PM EDT
Recruiting Phase 2 Interventional

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

NCT05786066
View directory record Official record
Conditions
Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
Interventions
Perampanel 6 MG, Ketamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Perampanel on Neurophysiology Test Perimeters

NCT03653741
View directory record Official record
Conditions
Healthy
Interventions
Perampanel 6 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

NCT00165789
View directory record Official record
Conditions
Parkinson's Disease
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Little Rock, Arkansas • Oxnard, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 2, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional Results available

Fycompa in Catamenial Epilepsy

NCT05201703
View directory record Official record
Conditions
Catamenial Epilepsy
Interventions
Fycompa, Fycompa with a boost
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 2, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability of Perampanel in Cervical Dystonia

NCT02131467
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Perampanel
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

NCT02120365
View directory record Official record
Conditions
Alcoholism
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 2, 2026, 11:33 PM EDT
Completed No phase listed Observational

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

NCT03208660
View directory record Official record
Conditions
Epilepsy
Interventions
Fycompa
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 2, 2026, 11:33 PM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00735397
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 2, 2026, 11:33 PM EDT
Terminated Phase 2 Interventional Results available

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

NCT00566462
View directory record Official record
Conditions
Parkinson's Disease
Interventions
perampanel, placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
New Haven, Connecticut • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 2, 2026, 11:33 PM EDT
Recruiting Phase 2 Interventional

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

NCT06401707
View directory record Official record
Conditions
Heart Arrest, Seizures, Status Epilepticus
Interventions
Perampanel, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 11:33 PM EDT
Completed Phase 1 Interventional

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

NCT03367533
View directory record Official record
Conditions
Depressive Disorder, Major, Post Traumatic Stress Disorder, Bipolar Disorder
Interventions
Ketamine, Perampanel, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 2, 2026, 11:33 PM EDT
Terminated Phase 3 Interventional Results available

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

NCT02834793
View directory record Official record
Conditions
Lennox-Gastaut Syndrome (LGS)
Interventions
Placebo, Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 2, 2026, 11:33 PM EDT